Novus Therapeutics Inc (NVUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Novus Therapeutics Inc (NVUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH135289D
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Novus Therapeutics Inc (Tokai Pharma), formerly Tokai Pharmaceuticals Inc is a pharmaceutical company that offers acquisition, development and commercialization of ear, nose and throat ENT products. The company's lead products is a nasally-administer, combination drug product and eustachian tube dysfunction, among others. Its galeterone is an oral small molecule drug candidate with treatment of patients with metastatic castration-resistant prostate cancer. Novus Therapeutics offers OP-02 surfactant program and OP-01 foam platform. Its pipeline also includes androgen receptor degradation agent's drug discovery program to identify and develop compounds for androgen receptor degradation activity. The company has collaboration with pharmaceutical companies to enhance its product candidates. Novus Therapeutics is headquartered in Irvine, California, the US.

Novus Therapeutics Inc (NVUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Novus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Novus Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Tokai Pharma Raises USD35.5 Million In Series E Financing 13

Tokai Pharma Raises USD23 Million In Series D3 Financing 15

Partnerships 16

Tokai Pharma Expands Agreement with Qiagen 16

Tokai Pharma Enters into Agreement with Qiagen 17

Licensing Agreements 18

Tokai Pharma Enters into Licensing Agreement with Johns Hopkins University 18

Tokai Pharma Amends Licensing Agreement with University of Maryland, Baltimore 19

Tokai Pharma Amends Licensing Agreement with University of Maryland, Baltimore 20

Equity Offering 21

Novus Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 21

Tokai Pharma Raises USD0.71 Million in Public Offering of Shares 22

Tokai Pharma Raises USD97.2 Million in IPO 23

Acquisition 25

Tokai Pharma Acquires Otic Pharma 25

Novus Therapeutics Inc-Key Competitors 27

Novus Therapeutics Inc-Key Employees 28

Novus Therapeutics Inc-Locations And Subsidiaries 29

Head Office 29

Recent Developments 30

Financial Announcements 30

Aug 09, 2017: Novus Therapeutics Reports Second Quarter 2017 Results 30

May 10, 2016: Tokai Pharmaceuticals Reports First Quarter 2016 Financial Results 31

Mar 10, 2016: Tokai Pharmaceuticals Reports Full Year 2015 Financial Results 32

Corporate Communications 33

Jun 12, 2017: Novus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 33

Jul 29, 2016: Tokai Pharmaceuticals Announces Reduction in Force 34

Product News 35

05/18/2016: Tokai Announces Publication of Three Abstracts on Galeterone at the 2016 ASCO Annual Meeting 35

04/13/2016: Tokai Announces Presentations on Galeterone at the AACR Annual Meeting 2016 36

01/08/2016: Tokai Announces Presentation of New Data Highlighting Unique Galeterone Mechanism at ASCO Genitourinary Cancers Symposium 37

Clinical Trials 38

Jul 26, 2016: Tokai Pharmaceuticals Announces Clinical Update 38

Apr 26, 2016: Tokai Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting 39

Mar 30, 2016: Tokai Announces Dosing of First Patient in Phase 2 Expansion Study of Galeterone in Enzalutamide-Refractory mCRPC Patients 40

Jan 07, 2016: Tokai Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42

List of Figures

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Novus Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11

List of Tables

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Novus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Novus Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Novus Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11

Novus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Tokai Pharma Raises USD35.5 Million In Series E Financing 13

Tokai Pharma Raises USD23 Million In Series D3 Financing 15

Tokai Pharma Expands Agreement with Qiagen 16

Tokai Pharma Enters into Agreement with Qiagen 17

Tokai Pharma Enters into Licensing Agreement with Johns Hopkins University 18

Tokai Pharma Amends Licensing Agreement with University of Maryland, Baltimore 19

Tokai Pharma Amends Licensing Agreement with University of Maryland, Baltimore 20

Novus Therapeutics Files Registration Statement to Raise Funds through Public Offering of Shares 21

Tokai Pharma Raises USD0.71 Million in Public Offering of Shares 22

Tokai Pharma Raises USD97.2 Million in IPO 23

Tokai Pharma Acquires Otic Pharma 25

Novus Therapeutics Inc, Key Competitors 27

Novus Therapeutics Inc, Key Employees 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Novus Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16195
Site License
USD 500 INR 32390
Corporate User License
USD 750 INR 48585

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com